A multi-institutional team, led by a group of investigators at 91°µÍø, has been studying various SARS-CoV-2 protein targets, including the virus’s main protease.
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.